Items where Author is "Kaiser, G."
 | Up a level |
Article
Schlitt, H. and Kaiser, G. and Richter, N. and Heyne, N. and Rauchfuss, F. and Neuhaus, P. and Schemmer, P. and Fischer, L. and Paulus, E. and Mertens, M. and Sterneck, M. (2013) The PROTECT Study: 35 Months of Everolimus Monotherapy vs. Calcineurin Inhibitor-Based Therapy Showed To Be a Safe Alternative with Superior Renal Function in Liver Transplant Recipients. AMERICAN JOURNAL OF TRANSPLANTATION, 13 (Suppl5). p. 130. ISSN 1600-6135, 1600-6143
Schlitt, H. J. and Kaiser, G. and Richter, N. and Heyne, N. and Rauchfuss, F. and Schemmee, P. and Fischer, L. and Paulus, E. -M. and Mertens, M. and Sterneck, M. (2013) The PROTECT Study: Everolimus Monotherapy vs. Calcineurin Inhibitor-Based Therapy over 35 Months Showed To Be a Safe Alternative with Superior Renal Function in Liver Transplant Recipients. LIVER TRANSPLANTATION, 19 (6Supp1). S88. ISSN 1527-6465, 1527-6473
Other
De Simone, P. and Fischer, L. and Kaiser, G. and Jonas, S. and Heise, M. and Schemmer, P. and Pascher, A. and Schlitt, H. and Paulus, E. and Mertens, M. and Duvoux, C. (2013) EARLY EVEROLIMUS PLUS REDUCED TACROLIMUS VERSUS STANDARD TACROLIMUS IN DE NOVO LIVER TRANSPLANT RECIPIENTS RESULTS IN SUPERIOR RENAL FUNCTION AND SUSTAINS OVER 24 MONTHS: RESULTS OF A RANDOMIZED TRIAL. WILEY-BLACKWELL, HOBOKEN.
Fung, J. and Fischer, L. and Kaiser, G. and Jonas, S. and Heise, M. and Schemmer, P. and Pascher, A. and Schlitt, H. and Paulus, E. and Mertens, M. and Nevens, F. (2013) EVEROLIMUS PLUS REDUCED TACROLIMUS IN DE NOVO LIVER TRANSPLANT RECIPIENTS ACHIEVES COMPARABLE OVERALL EFFICACY WITH FEWER BIOPSY-PROVEN ACUTE REJECTIONS VERSUS STANDARD TACROLIMUS: 24-MONTH RESULTS OF A RANDOMIZED TRIAL. WILEY-BLACKWELL, HOBOKEN.
Schlitt, H. and Kaiser, G. and Richter, N. and Heyne, N. and Rauchfuss, F. and Pascher, A. and Schemmer, P. and Fischer, L. and Paulus, E. and Mertens, M. and Sterneck, M. (2013) THE PROTECT STUDY: EFFECT OF 35 MONTH EVEROLIMUS MONOTHERAPY VS. CALCINEURIN INHIBITOR-BASED THERAPY ON EFFICACY AND RENAL FUNCTION IN LIVER TRANSPLANT RECIPIENTS. WILEY-BLACKWELL, HOBOKEN.
Sterneck, M. and Kaiser, G. and Richter, N. and Heyne, N. and Rauchfuss, F. and Neuhaus, P. and Schemmer, P. and Fischer, L. and Paulus, E. M. and Mertens, M. and Schlitt, H. J. (2013) THE PROTECT STUDY: EVEROLIMUS MONOTHERAPY vs. CALCINEURIN INHIBITOR-BASED THERAPY RESULTS IN PROGRESSIVE RENAL FUNCTION BENEFIT OVER 35 MONTHS IN LIVER TRANSPLANT RECIPIENTS. ELSEVIER SCIENCE BV, AMSTERDAM.
